Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;130(4):765-769.
doi: 10.1097/AOG.0000000000002253.

Tranexamic Acid for the Management of Obstetric Hemorrhage

Luis D Pacheco  1 , Gary D V Hankins, Antonio F Saad, Maged M Costantine, Giuseppe Chiossi, George R Saade
Affiliations

Tranexamic Acid for the Management of Obstetric Hemorrhage

Luis D Pacheco et al. Obstet Gynecol. 2017 Oct.

Abstract

Obstetric hemorrhage remains the most common cause of maternal mortality worldwide. It is believed that increased fibrinolytic activity, secondary to release and activation of endothelial tissue plasminogen activator, is involved in its pathogenesis. Tranexamic acid (TXA), an antifibrinolytic agent, has been shown to be beneficial in trauma patients if used within 3 hours of injury. A recent large randomized controlled trial showed that TXA given to hemorrhaging women within 3 hours after delivery was associated with decreased risk of death resulting from bleeding with no increase in thromboembolic complications. Limited evidence suggests that prophylactic TXA reduces blood loss at the time of delivery and decreases transfusion rates in the obstetric population. Tranexamic acid appears to be a safe and effective option in the treatment of obstetric hemorrhage. In addition, the limited available evidence supports the need for a well-designed adequately powered clinical trial to test its benefit as a prophylactic agent.

PubMed Disclaimer

Comment in

  • Tranexamic Acid for the Management of Obstetric Hemorrhage.
    Butwick AJ, Deneux-Tharaux C, Sentilhes L. Butwick AJ, et al. Obstet Gynecol. 2017 Dec;130(6):1386. doi: 10.1097/AOG.0000000000002384. Obstet Gynecol. 2017. PMID: 29189683 No abstract available.
  • In Reply.
    Pacheco LD, Hankins GDV, Saad AF, Costantine MM, Chiossi G, Saade GR. Pacheco LD, et al. Obstet Gynecol. 2017 Dec;130(6):1386-1387. doi: 10.1097/AOG.0000000000002385. Obstet Gynecol. 2017. PMID: 29189684 No abstract available.

References

    1. Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, Heuton KR, et al. Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:980–1004.
    1. Cohen MJ, Christie SA. Coagulopathy of trauma. Crit Care Clin 2017;33:101–18.
    1. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2017;376:136–48.
    1. Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987;69:460–6.
    1. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant hemorrhage (CRASH 2): a randomized placebo-controlled trial. Lancet 2010;376:23–32.

MeSH terms

LinkOut - more resources